This
report provides a comprehensive overview of the size of cancer immunotherapy
market, the segmentation of the market, key players and the vast potential of
therapies that are in clinical trials. Oncologic therapeutics cannot cure
cancer and yet in 2014, the overall market for cancer therapeutics stood at
about $84.3 billion. Any drug that can
provide a reasonable survival of more than five years for cancer patients can
achieve a blockbuster status. Within cancer therapeutics, immunotherapeutic
drugs have gained worldwide acceptance, because they are targeted drugs
targeting only cancer cells. Today, cancer immunotherapy drugs have captured
nearly 50% of the overall oncology drugs market, generating about $41.0 billion
in 2014 alone. This report describes the evolution of such a huge market in 20
chapters supported by over 180 tables and figures in 317 pages.
Get Full
Details On: http://www.radiantinsights.com/research/global-usa-cancer-immunotherapy-market-analysis-to-2020
•
An overview of cancer immunotherapy that includes: monoclonal antibodies,
cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
•
Focus on current trends in cancer immunotherapies that include: anti-PD-1
drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
•
Insight into the challenges faced by drug developers, particularly about the
success vs. failure ratios in developing cancer immunotherapy drugs.
•
Descriptions of more than 23 cancer immunotherapeutics approved and used as
targeted drugs
•
Insight into the various immunotherapeutics available for specific cancer
types.
•
Description and data for the prevalence of cancer types that are addressed by
cancer immunotherapeutics.
•
Overall global cancer therapeutics market, leading market players and the best
selling cancer drugs.
•
Detailed account of the market for cancer immunotherapeutics by geography,
indication, company and individual drugs.
•
Profiles, marketed products and products in the pipeline of 79 companies that
are mostly located in the U.S. and Europe.
• Summary table to identify the category of
immunotherapy drug offered by the 79 companies.
The
report is supported by over 180 tables & figures over 317 pages. This
report is presented as follows:
The
global market for cancer immunotherapy by the following sub-categories are
presented:
-By
Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies,
Checkpoint Inhibitors)
-By
Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal
Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell
Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT)
& IDO Inhibitors)
-By
Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech,
Roche, Bristol Myers Squibb)
About Us:
Radiant
Insights Inc. is a platform for companies looking to meet their market research
and business intelligence requirements. We assist and facilitate organizations
and individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
Contact
Details:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
28
2nd Street,
Suite
3036 San Francisco,
CA
94105 United States
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Website:
http://www.radiantinsights.com/
Email:
sales@radiantinsights.com
Visit our Blog:
http://chemicalsandmaterialsri.blogspot.com
No comments:
Post a Comment